Treatment of Parkinsonism

  • D. B. Calne
  • P. F. Teychenne
  • R. F. Pfeiffer
Part of the Advances in Experimental Medicine and Biology book series (AEMB)

Abstract

Over the last decade the treatment of Parkinsonism has under gone major developments. Advances deriving from a logically structured series of laboratory experiments have been transferred to the clinic to generate substantial therapeutic achievements.

Keywords

Dopamine Dementia Serotonin Neurol Alkaloid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cools, A.R. and Van Rossum, J.M. (1975). Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharma- cologia (Berl). 45 ,243–254.CrossRefGoogle Scholar
  2. Cotzias, G.C., Lawrence, W.H., Papavasiliou, P.S., Tolosa, E.S., Mendez, J.S. and Bell-Medura, M. (1976). Treatment of Park inson’s disease with aporphines, possible role of growth hormone. New Engl J. Med 294 ,567–572.PubMedCrossRefGoogle Scholar
  3. Creese, I.N., Bunt, D.R. and Snyder, S.H. (1976). Dopamine receptor binding; differentiation of agonist and antagonist states with 3H-holaperidol. Life Sci. 17 ,993–1002.CrossRefGoogle Scholar
  4. Greenacre, J.K., Coxon, A., Petrie, A. and Reid, J.L. (1976). Comparison of levodopa with carbidopa or benserazide in parkin-sonism. Lancet 2 ,381–384.PubMedCrossRefGoogle Scholar
  5. Jaton, A.L., Loew, D.M. and Vigouret, J.M. (1975). CF 25–397 (9,10 didehydro-6-methyl-8ß-[2-pyridylthiomethyl] ergoline), anew central dopamine receptor agonist. Proc B.P.S. 56 ,371.Google Scholar
  6. Kartzinel, R. and Calne, D.B. (1976). Studies with bromocriptine Part I. “On-off” phenomena. Neurology, 26 ,508–510.CrossRefGoogle Scholar
  7. Kartzinel, R., Perlow, M.J., Carter, A.C., Chase, T.N. and Calne, D.B. (1976). Metabolic studies with bromocriptine in patients with idiopathic Parkinsonism and Huntington’s Chorea. Trans Am Neurol Assoc. In press.Google Scholar
  8. Kartzinel, R., Perlow, M., Teychenne, P., Gielen, A., Gillespie, M., Sadowsky, D. and Calne, D.B. (1976). Bromocriptine and levodopa (with or without carbidopa) in Parkinsonism. Lancet 2 ,272–275.PubMedCrossRefGoogle Scholar
  9. Libet, B. and Tosaka, T. (1970). Dopamine as a synaptic transmitter and modulator in sympathetic ganglia: A different mode of synaptic action. Proc Nat Acad Sci USA 67 ,667–673.PubMedCrossRefGoogle Scholar
  10. Lieberman, A., Miyamoto, T., Battista, A. and Goldstein, M. (1975). Studies on the anti-Parkinsonian efficacy of lergotrile. Neurol. 25 ,459–462.CrossRefGoogle Scholar
  11. Lloyd, K.G., Davidson, L. and Hornykiewicz, O. (1973). Metabolism of levodopa in the human brain. In Advances in Neurology, Vol. 3, (Calne, D.B., Ed.) pp. 173–188. Raven Press, New York.Google Scholar
  12. Marsden, CD. and Parkes, J.D. (1976). “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1 ,292–296.PubMedCrossRefGoogle Scholar
  13. McLennan, H. and York, D.H. (1967). The action of dopamine on neurons of the caudate nucleus. J. Physiol. (Lond). 189 ,393–402.Google Scholar
  14. Reid, J.L., Calne, D.B., Vakil, S.D., Allen, J.C. and Davies, C.A. (1972). Plasma concentrations of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase. J. Neurol Sci. 17 ,45–51.PubMedCrossRefGoogle Scholar
  15. Silbergeld, E.K., Adler, H., Kennedy, S. and Calne, D.B. (1976).Roles of presynaptic dopamine function and hepatic drug metabolism in effects of three dopamine agonists: bromocriptine, lergotrile and CF25-397. In press.Google Scholar
  16. Silbergeld, E.K. and Pfeiffer, R.F. (1976). Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile. In press.Google Scholar
  17. Teychenne, P.F., Jones, A. and Calne, D.B. (1976). Changes in liver function induced by lergotrile. In preparation.Google Scholar
  18. Teychenne, P.F., Pfeiffer, R.F. and Calne, D.B. (1976). Actions of CF25–397 in parkinsonism. In preparation.Google Scholar
  19. Yahr, M.D. (ed.) (1973). In Advances in Neurology, Vol. 2-Treatment of Parkinson’s Disease-the Use of Dopa Deoarboxylase Inhibitors. pp. 303. Raven Press, New York.Google Scholar
  20. Yahr, M.D. (1975). Levodopa. Ann Intern Med. 83 ,667–682.Google Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • D. B. Calne
    • 1
    • 2
  • P. F. Teychenne
    • 1
    • 2
  • R. F. Pfeiffer
    • 1
    • 2
  1. 1.Experimental Therapeutics BranchNational Institute of Neurological and Communicative Disorders and StrokeBethesdaUSA
  2. 2.Department of Health, Education and WelfareNational Institutes of HealthBethesdaUSA

Personalised recommendations